Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3700 | Standard COVID-19 therapies Wiki | 0.71 |
| drug2610 | Non-invasive cardiac imaging Wiki | 0.71 |
| drug1278 | Drugs and supportive care Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.24 |
Navigate: Correlations HPO
There are 2 clinical trials
COVID-19 is increasingly affecting children but convalescent plasma (CP) has not been adequately studied in children to date. The study will determine safety of convalescent plasma for pediatric patients with severe, or at high risk for severe, COVID-19 disease.
Description: Safety of convalescent plasma for pediatric patients will be determined by capturing the grade 3-5 adverse events that are possible, probably or definitely related to the CP infusion, defined using the NCI Common Terminology Criteria for Adverse Events (CTCAE)
Measure: Number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma (CP) infusion Time: 28 daysDescription: Change in percent of supplemental oxygen within 72 hours after infusion
Measure: Change in percent of supplemental oxygen Time: Baseline, 72 hours after infusionDescription: Number of patients that required change in level of respiratory support such as nasal canula, non-invasive ventilation, mechanical ventilation, high frequency oscillator ventilation, and extracorporeal membrane oxygenation (ECMO)
Measure: Number of patients that required change in level of respiratory support Time: Baseline, 72 hours after infusionDescription: Number of deaths
Measure: Mortality Time: up to 1 yearDescription: Length of ICU stay (days) will be recorded
Measure: Mean length of ICU stay (days) Time: Up to 28 daysDescription: Length of hospital stay (days) will be recorded
Measure: Mean length of hospital stay (days) Time: Up to 28 daysDescription: Length of ventilation (days) will be recorded
Measure: Mean length of ventilation (days) Time: Up to 28 daysDescription: Number of patients with progression to renal dysfunction and/or multisystem organ failure will be recorded
Measure: Number of patients with progression to renal dysfunction and/or multisystem organ failure Time: up to 1 yearDescription: Cytokine milieu will be assayed by Luminex
Measure: IL-6 level Time: up to 28 daysDescription: Cellular studies will be used for evaluation of anti-SARS CoV 2 specific T cells
Measure: Number of anti-SARS CoV 2 specific T cells Time: up to 28 daysDescription: Cellular studies will be used for evaluation of diversity of circulating T cells
Measure: Diversity of circulating T cells Time: up to 28 daysDescription: Antibody titers to SARS-CoV-2 evaluation will be performed in vivo
Measure: ARS-CoV-2 Antibody Titer Time: up to 28 daysDescription: Neutralizing antibodies are a type of virus specific antibody that not only bind virus but bind in a manner that prevents viral infection. Test will be will be performed in vivo.
Measure: SARS-CoV-2 Neutralizing Titer Time: up to 28 daysThe outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred initially in December 2019 in the city of Wuhan, Hubei province, China. Patients mainly presented with respiratory symptoms and this novel pathogen was identified.At present, the core management of COVID-19 includes infection prevention, case detection, monitoring, and supportive care. While specific new drugs and vaccines are being researched, certain drugs that are already present in medical arsenal are under trial too. One investigational treatment being explored for COVID-19 is the use of convalescent plasma (CP) collected from recovered COVID-19 patients. Convalescent Plasma is a source of passive immune therapy- the administration of specific antibodies against a given agent for preventing or treating an infectious disease due to that agent. The main anticipated mechanism of action of Convalescent Plasma therapy in COVID19 is viral neutralization. Other possible mechanisms include antibody-dependent cellular cytotoxicity and phagocytosis. There are numerous examples in which convalescent plasma (CP) has been used successfully as post exposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses e.g. SARS-1, MERS-CoV and very recently in 2014, the Ebola virus outbreak. In SARS-CoV-2, Shen et al published a case series of 5 critically ill patients with COVID-19 and acute respiratory distress syndrome showing improvement in clinical status after transfusion of CP. Therefore, the objective of this study is to determine the safety and efficacy of transfusing convalescent plasma in patients admitted with COVID-19 at Aga Khan University Karachi, Pakistan. The investigators hypothesize that CP will decrease the length of hospital stay and overall mortality in patients with COVID-19. In this study, convalescent plasma will be collected from the donors who have been recovered from SARS-CoV-2 infection and transfused it to the patients admitted with active severe /critical COVID-19 at the Aga Khan University Hospital Karachi. STUDY DESIGN: Non-randomized open Label trial INCLUSION CRITERIA IN TREATMENT ARM: i. Inpatients at AKU with positive SARS-CoV-2 infection by rRT-PCR and who have provided written informed consent for inclusion in the trial; ii. Age ≥ 18 years; iii. Severe or immediately life-threatening COVID-19 defined by any of: - Respiratory rate ≥ 30/min; - Blood oxygen saturation ≤ 93% at room air; - Partial pressure of arterial Oxygen to Fraction of inspired Oxygen ratio < 300; - Lung infiltrates > 50% within 24 to 48 hours on radiology ( X-ray or CT scan); - Need for mechanical ventilation. - respiratory failure - septic shock - multiple organ dysfunction or failure EXCLUSION CRITERIA: i. Negative rRT-PCR from respiratory secretions or blood within 48 h prior to assessment of eligibility. ii. History of allergic reaction to blood or plasma products (as judged by the investigator). iii. Medical conditions in which receipt of 500 mL intravascular volume may be detrimental to the patient (e.g., actively decompensated congestive heart failure). iv. Enrolment in any other clinical trial for an investigational therapy. CONTROL GROUP: COVID-19 patients recruited during the period before CP becomes available or for whom no compatible CP is available will be given Standard of Care and will be followed for study outcomes. Data from these SC patients will be used as comparator in the analysis of the study.
Description: Decrease length of stay in hospital , Decrease length of stay in ICU/special care unit
Measure: Decrease length of stay Time: From date on which intervention given until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 monthDescription: Status alive or death
Measure: Overall mortality Time: From date on which intervention given until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 monthDescription: Any adverse event after the transfusion of Convalescent plasma which include TRALI, TACO, allergic reaction, anaphylaxis.
Measure: Incidence of adverse events related to Convalescent Plasma transfusion Time: After receiving intervention (CP) till 24 hoursDescription: Modified from WHO scale. It includes clinical status of patient in terms of respiratory support needed.
Measure: Ordinal scale Time: From date on which intervention given until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 monthDescription: Time to improvement in serum ferritin levels after intervention
Measure: Improvement in Laboratory Parameters: Serum Ferritin Time: From date on which intervention given until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 monthDescription: Time to improvement in serum Procalcitonin levels after intervention
Measure: Improvement in Laboratory Parameters: Procalcitonin Time: From date on which intervention given until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 monthDescription: Time to improvement in C-Reactive protein levels after intervention
Measure: Improvement in Laboratory Parameters: C-Reactive Protein Time: From date on which intervention given until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 monthDescription: Time to improvement in D-Dimer levels after intervention
Measure: Improvement in Laboratory Parameters: D-Dimer Time: From date on which intervention given until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 monthDescription: Time to improvement in complete blood count after intervention
Measure: Improvement in Laboratory Parameters: Complete Blood count Time: From date on which intervention given until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 monthDescription: Time to improvement in chest X-Ray findings after intervention
Measure: Chest X-Ray findings Time: From date on which intervention given until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 monthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports